Fundus hypopigmentation and choroidal thinning associated with tebentafusp therapy: report of a case and literature review
Tebentafusp therapy can lead to diffuse fundus hypopigmentation and choroidal thinning, similar to what has been reported after immune checkpoint inhibition. The progressive choroidal hypopigmentation, without evidence of associated intraocular inflammation, indicates that glycoprotein 100, the target antigen of tebentafusp, is also expressed by normal choroidal melanocytes.
Authors
- Ragnhild Wivestad Jansson (ORCID: https://orcid.org/0000-0003-1227-7843)
- O. Straume
- Jørgen Krohn (ORCID: https://orcid.org/0000-0003-4783-2974)
- Liv Iren Hansen Vinnem
Institutions
- Haukeland University Hospital (NO)
- University of Bergen (NO)
Publication Details
- Journal
- BMC Ophthalmology
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1186/s12886-025-04274-7
- Primary Topic
- melanin and skin pigmentation
- Type
- article
- Field-Weighted Citation Impact
- 0.00